funding for PSMA PET CT scans, study examining [18F]DCFPyL PET/CT in biochemical failure, detection of prostate cancer in low PSA groups, IMPPORT clinical trial, management of prostate cancer patients with low PSA.
APCCC 2024, Digital Rectal Examination (DRE), Local T-Stage, multi-parametric MRI (mpMRI), PROBASE trial, PRECISION trial, PRIMARY trial, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET),…
urology, endourology, endourology mentorship, urology mentorship, Endourological Society’s accreditation, Endourological Society-accredited urology fellowship programs, future of urological care and research.
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…
bladder cancer, Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma, Atezolizumab, IMvigor130 trial, metastatic urothelial carcinoma (mUC), PD-L1 expression, CheckMate 901…
bladder cancer (BC), neoadjuvant chemotherapy after radical cystectomy (RC), gemcitabine/cisplatin, MVAC/dose-dense MVAC, gemcitabine/carboplatin, circulating tumor DNA.
prostate cancer, Prostate specific membrane antigen (PSMA), positron emission tomography (PET), PSMA PET, PSMA-radioguided surgery (PSMA-RGS), PSMA-Radioguided Surgery in Recurrent Prostate Cancer, Robot-Assisted and Open…
Genetic alterations in fibroblast growth factor receptors (FGFRs), urothelial carcinoma, FGFR3 or FGFR2 genetic alterations, non-muscle invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC).
prostate cancer, grade group 2 prostate cancer, ProtecT trial, International Society of Urological Pathologists (ISUP), ISUP grading system, radical prostatectomy, low-grade prostate cancer.
Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in…
Andrea Miyahira hosts Ping Mu to discuss his group’s research on prostate cancer resistance to anti-androgens. Dr. Mu’s study, published in Oncogene, focuses on the…
